Education 【 display / non-display 】

Education 【 display / non-display 】

• 2011

  -

  2019

  Sapporo Medical University   Graduate School of Medicine  

• 2002

  -

  2008

  Sapporo Medical University   医学部   医学科  

Degree 【 display / non-display 】

Degree 【 display / non-display 】

• 2019.03   Sapporo Medical University   Doctor of Medicine

Research Experience 【 display / non-display 】

Research Experience 【 display / non-display 】

• 2023.04

  -

  Now

  Sapporo Medical University   放射線医学講座   助教

• 2020.01

  -

  2023.03

  手稲渓仁会病院   放射線治療科   主任医長

• 2020.01

  -

  2023.03

  Sapporo Medical University   放射線医学講座   研究員

• 2019.04

  -

  2019.12

  Sapporo Medical University   放射線医学講座   助教

• 2015.10

  -

  2016.09

  Sapporo Medical University   放射線医学講座   特任助教

Professional Memberships 【 display / non-display 】

Professional Memberships 【 display / non-display 】

• 2011.02

  -

  Now

  日本放射線腫瘍学会

• 2010.07

  -

  Now

  日本医学放射線学会

Research Areas 【 display / non-display 】

Research Areas 【 display / non-display 】

• Life sciences   Radiology  

Affiliation 【 display / non-display 】

Affiliation 【 display / non-display 】

• Sapporo Medical University   放射線医学講座   助教  

Research Interests 【 display / non-display 】

Research Interests 【 display / non-display 】

• DNA損傷修復

• 放射線腫瘍学

• リキッドバイオプシー

Papers 【 display / non-display 】

Papers 【 display / non-display 】

• Prediction of Treatment Response Based on Nutritional Status and Tumor Immunity in Oropharyngeal Cancer Patients Treated With Chemoradiotherapy.

  Mio Kitagawa, Juno Kaguchi, Masanori Someya, Yuki Fukushima, Tomokazu Hasegawa, Takaaki Tsuchiya, Toshio Gocho, Shoh Mafune, Yutaro Ikeuchi, Ryu Okuda, Atsuya Ohguro, Ryo Kamiyama, Ayato Ashina, Yuka Toshima, Yoshihiko Hirohashi, Toshihiko Torigoe, Koh-Ichi Sakata

  Cancer diagnosis & prognosis   4 ( 6 ) 789 - 796  2024  [Refereed]  [International journal]

  Authorship：   Lead author

  　View Summary

  BACKGROUND/AIM: Radiotherapy (RT) for advanced oropharyngeal cancer (OPC) is effective, especially when combined with chemotherapy (CRT). However, its success can vary depending on factors, such as tumor stage, HPV infection (p16 status), and the patient's nutritional and immune status. This study examined the controlling nutritional status (CONUT) score and tumor immunity as predictive factors for treatment outcomes in OPC, aiming to develop a personalized risk score. PATIENTS AND METHODS: A retrospective analysis was conducted on 84 patients with OPC treated with definitive RT or CRT, and survival outcomes were compared based on various factors, including BMI, CONUT score, CD8 expression, and HLA class II expression. RESULTS: We observed better overall survival (OS) rates in CD8-positive patients and those with higher HLA class II expression. The univariate analysis identified stage, p16 status, BMI, CONUT score, and CD8 expression as significantly associated with OS. In multivariate analysis, stage, BMI, and CONUT score remained significant predictors of OS. A risk scoring system was developed based on stage, p16 status, BMI, CONUT score, and CD8 expression. Patients were categorized into low-risk and high-risk groups, with significantly better survival in the low-risk group. CONCLUSION: A combined risk score incorporating clinical, nutritional, and immune factors can improve the prediction of treatment outcomes for OPC patients. This risk stratification may enable personalized treatment plans and improve ΟS rates.

  DOI PubMed

• Influence of XRCC4 expression by breast cancer cells on ipsilateral recurrence after breast-conserving therapy.

  Mio Kitagawa, Masanori Someya, Tomokazu Hasegawa, Toshihiko Mikami, Kazuaki Asaishi, Tadashi Hasegawa, Yoshihisa Matsumoto, Goro Kutomi, Ichiro Takemasa, Koh-Ichi Sakata

  Strahlentherapie und Onkologie : Organ der Deutschen Rontgengesellschaft ... [et al]   195 ( 7 ) 648 - 658  2019.07  [Refereed]  [International journal]

  Authorship：   Lead author

  　View Summary

  BACKGROUND: We examined the expression of nonhomologous end-joining (NHEJ) proteins by breast cancer cells in patients with or without ipsilateral breast tumor recurrence (IBTR) after breast-conserving therapy. We also investigated whether there was a difference of NHEJ-related protein expression by tumor cells between two types of IBTR, i.e., true recurrence (TR) with regrowth from the tumor bed or development of a new primary tumor (NP). PATIENTS AND METHODS: The original cohort comprised 560 breast cancer patients who received breast-conserving therapy between February 1995 and March 2006, including 520 patients without IBTR and 40 patients with IBTR. Propensity score matching was employed to select 40 trios (120 patients) consisting of 1 patient with IBTR and 2 patients without IBTR. Immunohistochemical examination of proteins related to NHEJ was performed in surgical specimens. RESULTS: The 40 patients with IBTR included 22 patients who developed TR and 18 who had NP. The 15-year overall survival rate was 85.9% for patients with NP and 95.5% for those with TR, while it was 96.5% for patients without IBTR. Patients with high XRCC4 expression in tumor cells had significantly higher IBTR rates than those with low XRCC4 expression (P < 0.001). The frequency of TR was significantly higher in patients with high expression of XRCC4 than in those with low XRCC4 expression (p < 0.001). XRCC4 expression by tumor cells was not significantly related to development of NP. CONCLUSION: IBTR due to TR may be related to low radiosensitivity of tumor cells, possibly related to high XRCC4 expression.

  DOI PubMed

• Analysis of Treatment Response With Proteins Related to Tumor Immunity in Postoperative Irradiated Cervical Cancer Patients.

  Shoh Mafune, Masanori Someya, Tomokazu Hasegawa, Takaaki Tsuchiya, Mio Kitagawa, Toshio Gocho, Ryu Okuda, Masahiro Iwasaki, Motoki Matsuura, Terufumi Kubo, Yoshihiko Hirohashi, Toshihiko Torigoe, Tsuyoshi Saito, Koh-Ichi Sakata

  Anticancer research   44 ( 7 ) 3077 - 3086  2024.07  [Refereed]  [International journal]

  　View Summary

  BACKGROUND/AIM: This study evaluated the association between programmed cell death-ligand 1 (PD-L1) and prognosis in patients with cervical cancer treated with postoperative radiation and the impact of neoadjuvant chemotherapy (NAC) on this association. PATIENTS AND METHODS: Immunohistochemical analysis was performed on biopsy specimens from 42 patients who did not receive NAC and from paired samples before (biopsies) and after (resected tissues) chemotherapy from 46 patients who received NAC to determine the association of PD-L1 with radiotherapy outcomes. RESULTS: In the non-NAC group, patients with ≥10% PD-L1-expressing tumor cells prior to treatment had better recurrence-free survival (RFS) than those with <10% PD-L1-expressing tumor cells (p=0.001). In the NAC group, RFS was significantly lower (p=0.005) in the group with a ≥5% reduction of PD-L1 expression in tumor cells after chemotherapy than in those with <5% reduction. In multivariate analysis, only PD-L1 expression (non-NAC group) and the change in PD-L1 expression (NAC group) were associated with RFS. CONCLUSION: Low PD-L1 expression in a cervical tumor prior to treatment was identified as a risk factor for a poor outcome after postoperative radiotherapy. Furthermore, NAC induces an immunological shift that reduces PD-L1 levels in tumor cells, thereby negatively impacting treatment outcomes.

  DOI PubMed

• Identification and Quantification of Radiotherapy-related Protein Expression in Cancer Tissues Using the Qupath Software and Prediction of Treatment Response.

  Tomokazu Hasegawa, Masanori Someya, Takaaki Tsuchiya, Mio Kitagawa, Yuki Fukushima, Toshio Gocho, Shoh Mafune, Ryuu Okuda, Juno Kaguchi, Atsuya Ohguro, Ryo Kamiyama, Ayato Ashina, Yuka Toshima, Yoshihiko Hirohashi, Toshihiko Torigoe, Koh-Ichi Sakata

  In vivo (Athens, Greece)   38 ( 3 ) 1470 - 1476  2024  [Refereed]  [International journal]

  　View Summary

  BACKGROUND/AIM: Automated measurement of immunostained samples can enable more convenient and objective prediction of treatment outcome from radiotherapy. We aimed to validate the performance of the QuPath image analysis software in immune cell markers detection by comparing QuPath cell counting results with those of physician manual cell counting. PATIENTS AND METHODS: CD8- and FoxP3-stained cervical, CD8-stained oropharyngeal, and Ku70-stained prostate cancer tumor sections were analyzed in 104 cervical, 92 oropharyngeal, and 58 prostate cancer patients undergoing radiotherapy at our Institution. RESULTS: QuPath and manual counts were highly correlated. When divided into two groups using ROC curves, the agreement between QuPath and manual counts was 89.4% for CD8 and 88.5% for FoxP3 in cervical cancer, 87.0% for CD8 in oropharyngeal cancer and 80.7% for Ku70 in prostate cancer. In cervical cancer, the high CD8 group based on QuPath counts had a better prognosis and the low CD8 group had a significantly worse prognosis [p=0.0003; 5-year overall survival (OS), 65.9% vs. 34.7%]. QuPath counts were more predictive than manual counts. Similar results were observed for FoxP3 in cervical cancer (p=0.002; 5-year OS, 62.1% vs. 33.6%) and CD8 in oropharyngeal cancer (p=0.013; 5-year OS, 80.2% vs. 47.2%). In prostate cancer, high Ku70 group had worse and low group significantly better outcome [p=0.007; 10-year progression-free survival (PFS), 56.0% vs. 93.8%]. CONCLUSION: QuPath showed a strong correlation with manual counting, confirming its utility and accuracy and potential applicability in clinical practice.

  DOI PubMed

• Prediction of late adverse events in pelvic cancer patients receiving definitive radiotherapy using radiation-induced gamma-H2AX foci assay.

  Masanori Someya, Tomokazu Hasegawa, Asako J Nakamura, Takaaki Tsuchiya, Mio Kitagawa, Toshio Gocho, Sho Mafune, Yutaro Ikeuchi, Hiroshi Tauchi, Koh-Ichi Sakata

  Journal of radiation research   64 ( 6 ) 948 - 953  2023.11  [Refereed]  [International journal]

  　View Summary

  Radiation can induce DNA double-stranded breaks, which are typically detected by the fluorescence of phosphorylated histone H2AX. In this study, we examined the usefulness of the dynamics of radiation-induced gamma-H2AX foci of peripheral blood lymphocytes (PBLs), as a marker of DNA repair ability, in predicting late adverse events from radiotherapy. A total of 46 patients with cervical, vaginal and anal canal cancers treated with radical radiotherapy between 2014 and 2019 were included in this analysis. Concurrent chemotherapy was administered in 36 cases (78.3%). Peripheral blood was obtained before treatment, and then irradiated ex vivo with 1 Gy X-ray. The ratio of radiation-induced gamma-H2AX foci in PBLs measured at 30 min and at 4 h was defined as the foci decay ratio (FDR). With a median follow-up of 54 months, 9 patients (19.6%) were observed to have late genitourinary or gastrointestinal (GU/GI) toxicity. The FDR ranged from 0.51 to 0.74 (median 0.59), with a significantly higher incidence of Grade 1 or higher late adverse events in the FDR ≥ 0.59 group. In multivariate analysis, FDR ≥ 0.59 and hypertension also emerged as significant factors associated with the development of late toxicities. Overall, our results suggest that measurement of radiation-induced gamma-H2AX foci in PBLs may predict the risk of late GU/GI toxicities from chemoradiotherapy, which can enable tailoring the radiation dose to minimize adverse effects.

  DOI PubMed

display all >>

Misc 【 display / non-display 】

Misc 【 display / non-display 】

• 動注化学放射線療法と外科手術を行った口腔癌の免疫組織学的評価

  染谷正則, 池内佑太郎, 眞船翔, 長谷川智一, 土屋高旭, 北川未央, 後町俊夫, 坂田耕一

  日本免疫治療学会学術集会プログラム・抄録集   21st  2024

  J-GLOBAL

• 当院において根治的放射線治療を行った食道癌症例の検討

  大黒敦矢, 眞船翔, 戸島有香, 芦名彩斗, 上山凌央, 後町俊夫, 土屋高旭, 北川未央, 長谷川智一, 染谷正則

  北海道医学雑誌   99 ( 2 )  2024

  J-GLOBAL

• 放射線感受性の個人差に基づく次世代の放射線治療と放射線防護 腫瘍および正常組織の放射線感受性予測に基づいた個別化放射線治療の実践(Personalized radiotherapy based on the prediction of radiosensitivity of tumors and normal tissues)

  Someya Masanori, Hasegawa Tomokazu, Tsuchiya Takaaki, Kitagawa Mio, Gocho Toshio, Mafune Shoh, Sakata Koh-ichi

  日本放射線影響学会大会講演要旨集 ( (一社)日本放射線影響学会 )  66回   12 - 12  2023.11

• 化学放射線+免疫療法を行った3期NSCLCにおける、末梢血リンパ細胞のTCRレパトア解析

  染谷 正則, 長谷川 智一, 北川 未央, 土屋 高旭, 後町 俊夫, 眞船 翔, 金関 貴幸, 蒔田 芹奈, 鳥越 俊彦, 坂田 耕一

  日本癌治療学会学術集会抄録集 ( (一社)日本癌治療学会 )  61回   O46 - 3  2023.10

• 末梢血リンパ球TCRレパトア解析を用いたNSCLCの治療効果予測(Prediction of Treatment Response in NSCLC using Peripheral Blood Lymphocyte TCR Repertoire Analysis)

  Someya Masanori, Hasegawa Tomokazu, Kitagawa Mio, Tsuchiya Takaaki, Fukushima Yuki, Gocho Toshio, Mafune Shou, Kanaseki Takayuki, Tokita Serina, Sakata Koh-ichi

  日本医学放射線学会学術集会抄録集 ( (公社)日本医学放射線学会 )  82回   S173 - S173  2023.03

display all >>

Research Projects 【 display / non-display 】

Research Projects 【 display / non-display 】

• リキッドバイオプシーを用いた肺癌放射線治療効果および有害事象発症の予測

  若手研究

  Project Year :

  2023.04

  -

  2026.03

   

  北川 未央

• リキッドバイオプシーを用いた肺癌個別化放射線治療の検討

  若手研究

  Project Year :

  2019.04

  -

  2023.03

   

  北川 未央

  　View Summary

  本研究は、化学放射線治療を行う原発性肺癌患者に対して、DNA損傷修復や免疫チェックポイントに関連するタンパク発現を免疫組織染色によって調べ、末梢血リンパ球や血中に含まれるエクソソーム（細胞外小胞）に内包されるmRNAおよびmicroRNAの発現を解析し、放射線治療効果や放射線性肺障害を予測するバイオマーカー探索を行うことを目的としている。 2020年度は、肺癌化学放射線治療後に抗PD-L1抗体であるデュルバルマブ投与を行う7名の患者より、照射前、照射後に血液を採取し、血漿およびリンパ球などの試料を分離採取した。また、生検検体におけるDNA損傷修復タンパクおよび免疫チェックポイントに関わるタンパク発現の免疫組織染色解析や、対象患者の進行度等の臨床因子やDose Volume Histogram上で算出される肺V20やV5、Mean Lung Doseなどのパラメータと放射線治療効果、放射線肺障害との関連性についての解析を進めた。 これまで我々のグループでは、免疫組織染色を用いて腫瘍組織におけるDNA損傷修復に関わるタンパク発現と放射線治療効果の関係について研究しており、また、免疫チェックポイントに関わるタンパク発現と放射線治療効果についても報告している。これらのタンパク発現および血中の腫瘍由来エクソソーム内のmRNA/miRNA発現解析を組み合わせることによってで、独自性高くかつ簡便なバイオマーカーの探索が可能であり、肺癌に対する個別化放射線治療の実現を目指すことが可能と考えられる。

• Development of a practical radiosensitivity prediction method for clinical applications

  Grant-in-Aid for Scientific Research (C)

  Project Year :

  2018.04

  -

  2021.03

   

  Sakata Koh-ichi

  　View Summary

  Using biopsy and surgical specimens of breast and cervical cancers, we analyzed the correlation between various protein expressions and radiotherapy outcomes. Radiotherapy of cervical cancer increased the expression of PD-L1 in tumor cells, and there was a strong correlation between the expression of PD-L1 in tumor cells after radiotherapy and overall survival. This suggests that irradiation-induced immunological changes may affect the radiotherapy effect. In patients with early-stage breast cancer treated with postoperative radiotherapy, XRCC4 expression rates in tumor cells were significantly correlated with intra-breast recurrence. By type of recurrence, there was a correlation with XRCC4 expression in True recurrence. True recurrence may be due to the low radiosensitivity of tumor cells.

• Development of methods predicting radiosensitivity that can be clinically applied

  Grant-in-Aid for Scientific Research (C)

  Project Year :

  2015.04

  -

  2018.03

   

  Sakata Koh-ichi

  　View Summary

  We developed a practical method for predicting radiosensitivity to realize individualized radiotherapy according to the biological characteristics of cancer cells. In uterine cervical cancer and prostate cancer, the correlation between expression proteins involved in repair of DNA double-strand breaks of tumor cells by biopsy specimens and radiotherapy results is analyzed, which is a predictive factor of therapeutic effect. In uterine cervical cancer, the expression rates of Ku 86 and XRCC 4 were predictors of the radiotherapeutic effect on cervical cancer. In prostate cancer, the expression of Ku70 in prostate cancer cells is a prognostic factor independent of clinical factors, and it has been shown that in addition to the prognostic factors presently used in clinical practice, recurrence after radiation treatment can be predicted with high accuracy.